- Home
- /
- Tirzepatide 50mg
Tirzepatide 50mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist — a single molecule that activates both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual mechanism represents a significant advancement over single-target GLP-1 agonists.
Tirzepatide is one of the most studied compounds in recent pharmaceutical history, with extensive clinical trial data from the SURPASS and SURMOUNT programmes demonstrating unprecedented efficacy in metabolic research. It has received FDA approval as Mounjaro (diabetes) and Zepbound (weight management).
Kyrolab supplies tirzepatide across 6 dosage variants from 10mg to 60mg, with independent COA verification across multiple suppliers and dose levels. This is the most comprehensively verified compound in our catalogue.
COA pending. Our Tirzepatide has been verified at 30mg (99.708%-99.847% across 3 suppliers) and 60mg (99.878%). Same compound across all dosages.
Specifications
| Molecular Weight | 4813.45 g/mol |
| CAS | 2023788-19-2 |
| Receptor | Dual GIP/GLP-1R agonist |
| Half-life | ~5 days (preclinical) |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
| Dose | 50mg per vial |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-TIRZEPATIDE50MG |
| Compound Name | Tirzepatide 50mg |